These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 17368754)

  • 1. Sunitinib malate and sorafenib may be beneficial at the treatment of advanced bladder cancer due to their anti-angiogenic effects.
    Silay MS; Miroglu C
    Med Hypotheses; 2007; 69(4):892-5. PubMed ID: 17368754
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Angiogenesis targeting in renal carcinomas].
    Pouessel D; Culine S
    Bull Cancer; 2007; 94(7 Suppl):F223-6. PubMed ID: 17965000
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sunitinib, sorafenib and mTOR inhibitors in renal cancer.
    Radulovic S; Bjelogrlic SK
    J BUON; 2007 Sep; 12 Suppl 1():S151-62. PubMed ID: 17935273
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sorafenib and sunitinib in the treatment of advanced non-small cell lung cancer.
    Gridelli C; Maione P; Del Gaizo F; Colantuoni G; Guerriero C; Ferrara C; Nicolella D; Comunale D; De Vita A; Rossi A
    Oncologist; 2007 Feb; 12(2):191-200. PubMed ID: 17296815
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-angiogenic therapy: concept to clinic.
    Young RJ; Reed MW
    Microcirculation; 2012 Feb; 19(2):115-25. PubMed ID: 22078005
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In pursuit of new anti-angiogenic therapies for cancer treatment.
    Cai J; Han S; Qing R; Liao D; Law B; Boulton ME
    Front Biosci (Landmark Ed); 2011 Jan; 16(3):803-14. PubMed ID: 21196204
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Angiogenesis as a therapeutic target in urothelial carcinoma.
    Pinto A; Redondo A; Zamora P; Castelo B; Espinosa E
    Anticancer Drugs; 2010 Nov; 21(10):890-6. PubMed ID: 20729712
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antitumor effects of sunitinib or sorafenib in patients with metastatic renal cell carcinoma who received prior antiangiogenic therapy.
    Tamaskar I; Garcia JA; Elson P; Wood L; Mekhail T; Dreicer R; Rini BI; Bukowski RM
    J Urol; 2008 Jan; 179(1):81-6; discussion 86. PubMed ID: 17997441
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The role of angiogenesis in renal carcinoma].
    Bussolati B; Satolli MA; Camussi G
    G Ital Nefrol; 2008; 25(3):297-305. PubMed ID: 18473301
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Effect of angiogenesis inhibitors on renal cell carcinoma].
    Bodrogi I
    Magy Onkol; 2007; 51(2):145-53. PubMed ID: 17660871
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Oral drugs inhibiting the VEGF pathway].
    Ropert S; Mir O; Armand JP
    Bull Cancer; 2007 Jul; 94 Spec No():S180-90. PubMed ID: 17846003
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Angiogenesis and renal cell carcinoma].
    Billemont B; Méric JB; Izzedine H; Taillade L; Sultan-Amar V; Rixe O
    Bull Cancer; 2007 Jul; 94 Spec No():S232-40. PubMed ID: 17846009
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Playing only one instrument may be not enough: limitations and future of the antiangiogenic treatment of cancer.
    Quesada AR; Medina MA; Alba E
    Bioessays; 2007 Nov; 29(11):1159-68. PubMed ID: 17935210
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Antiangiogenics: new therapeutic standards in metastatic kidney cancer].
    Cornu JN; Rouprêt M; Bensalah K; Oudard S; Patard JJ
    Prog Urol; 2008 Jul; 18 Suppl 4():S69-76. PubMed ID: 18706374
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sorafenib and sunitinib: novel targeted therapies for renal cell cancer.
    Grandinetti CA; Goldspiel BR
    Pharmacotherapy; 2007 Aug; 27(8):1125-44. PubMed ID: 17655513
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting angiogenesis in esophagogastric adenocarcinoma.
    Okines AF; Reynolds AR; Cunningham D
    Oncologist; 2011; 16(6):844-58. PubMed ID: 21632459
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antiangiogenic therapy for breast cancer.
    Nielsen DL; Andersson M; Andersen JL; Kamby C
    Breast Cancer Res; 2010; 12(5):209. PubMed ID: 21067536
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hemangiopericytoma and antiangiogenic therapy: clinical benefit of antiangiogenic therapy (sorafenib and sunitinib) in relapsed malignant haemangioperyctoma /solitary fibrous tumour.
    Domont J; Massard C; Lassau N; Armand JP; Le Cesne A; Soria JC
    Invest New Drugs; 2010 Apr; 28(2):199-202. PubMed ID: 19352594
    [No Abstract]   [Full Text] [Related]  

  • 19. Complete remission achieved with angiogenic therapy in metastatic renal cell carcinoma including surgical intervention.
    Staehler M; Haseke N; Zilinberg E; Stadler T; Karl A; Siebels M; Dürr HR; Siegert S; Jauch KW; Bruns CJ; Stief CG
    Urol Oncol; 2010; 28(2):139-44. PubMed ID: 19576802
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential drug class-specific metastatic effects following treatment with a panel of angiogenesis inhibitors.
    Chung AS; Kowanetz M; Wu X; Zhuang G; Ngu H; Finkle D; Komuves L; Peale F; Ferrara N
    J Pathol; 2012 Aug; 227(4):404-16. PubMed ID: 22611017
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.